High quantities of quality RNA are necessary for many veterinary laboratory tests. Several commercial kits are available for RNA isolation from human whole blood; their resultant RNA yield and purity have not been reported for canine whole blood, to our knowledge. We assessed the performance of 4 RNA extraction kits (RiboPure, TRIzol, RNeasy Protect animal blood, and QIAamp RNA blood mini). Whole blood from a healthy dog was stored in the manufacturer-recommended RNA stabilizing buffer as directed. RNA isolation, including DNase treatment, was performed using each kit's manufacturer's protocol. Resultant RNA yield and purity were evaluated using spectrophotometric absorbance, capillary electrophoresis and electropherogram analysis, and a reverse-transcription real-time PCR (RT-rtPCR) assay. The RNeasy Protect animal blood kit extracted the highest, and RiboPure the lowest, concentration of nucleic acid. RNA integrity numbers classified extracted RNA as good quality or better for all kits except RNeasy Protect. All kits had evidence of genomic DNA contamination as assessed by RT-rtPCR. Overall, QIAamp RNA blood mini kit and TRIzol optimized both RNA yield and purity from canine whole blood. These kits extracted high quantities of good quality RNA as evidenced by high RNA integrity numbers and minimal contamination with proteins and solvents.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488962 | PMC |
http://dx.doi.org/10.1177/1040638720938026 | DOI Listing |
Front Immunol
December 2024
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with the worst prognosis among all subtypes. The impact of distinct cell subpopulations within the tumor microenvironment (TME) on TNBC patient prognosis has yet to be clarified.
Methods: Utilizing single-cell RNA sequencing (scRNA-seq) integrated with bulk RNA sequencing (bulk RNA-seq), we applied Cox regression models to compute hazard ratios, and cross-validated prognostic scoring using a GLMNET-based Cox model.
Front Immunol
December 2024
Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States.
Introduction: Rhesus macaques have long been a focus of research for understanding immune responses to human pathogens due to their close phylogenetic relationship with humans. As rhesus macaque antibody germlines show high degrees of polymorphism, the spectrum of database-covered genes expressed in individual macaques remains to be determined.
Methods: Here, four rhesus macaques infected with SHIV became a study of interest because they developed broadly neutralizing antibodies against HIV-1.
Front Immunol
December 2024
Division of Rheumatology, University of Washington, Seattle, WA, United States.
Introduction: Neutrophil activation is important in systemic lupus erythematosus (SLE). We previously demonstrated that ribonucleoprotein (RNP) immune complexes (ICs) promoted neutrophil activation in a TLR7/8-dependent manner. However, it remains unclear if this mechanism occurs in patients.
View Article and Find Full Text PDFExp Ther Med
February 2025
Department of Biochemistry, Faculty of Science, Beni-Suef University, Beni-Suef 62511, Egypt.
Inefficient control of elevated blood sugar levels can lead to certain health complications such as diabetic nephropathy (DN) and cardiovascular disease (CVD). The identification of effective biomarkers for monitoring diabetes was performed in the present study. The present study aimed to investigate the implications of long non-coding RNA megacluster (lnc-MGC), microRNA (miR)-132 and miR-133a, and their correlation with lactate dehydrogenase (LDH) activity and glycated hemoglobin (HbA1C) levels to identify biomarkers for the early diagnosis of diabetes mellitus, induced DN and CVD.
View Article and Find Full Text PDFTheranostics
January 2025
Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly due to the limited effectiveness of current therapeutic options for advanced-stage disease. The efficacy of traditional treatments is often compromised by the intricate liver microenvironment and the inherent heterogeneity. RNA-based therapeutics offer a promising alternative, utilizing the innovative approach of targeting aberrant molecular pathways and modulating the tumor microenvironment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!